共 38 条
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice
被引:110
|作者:
Migliorini, Domenico
[1
,2
]
Bogaerts, Sven
[2
]
Defever, Dieter
[2
]
Vyas, Rajesh
[1
]
Denecker, Geertrui
[2
]
Radaelli, Enrico
[3
,4
]
Zwolinska, Aleksandra
[1
,2
]
Depaepe, Vanessa
[2
]
Hochepied, Tino
[5
]
Skarnes, William C.
[6
]
Marine, Jean-Christophe
[1
,2
]
机构:
[1] VIB KU Leuven, Lab Mol Canc Biol, Dept Mol & Dev Genet, B-3000 Louvain, Belgium
[2] VIB UGent, Lab Mol Canc Biol, Dept Biomed Mol Biol, Ghent, Belgium
[3] Univ Milan, Fac Vet Med, Dept Vet Pathol Hyg & Publ Hlth, Milan, Italy
[4] Fdn Filarete, Milan, Italy
[5] VIB UGent, Transgen Core Facil, Ghent, Belgium
[6] Wellcome Trust Sanger Inst, Cambridge, England
基金:
比利时弗兰德研究基金会;
关键词:
UBIQUITIN LIGASE COP1;
CELL-CYCLE PROGRESSION;
N-TERMINAL KINASE;
IN-VIVO;
TRANSCRIPTIONAL ACTIVITY;
PROSTATE-CANCER;
TRANSGENIC MICE;
BETHESDA PROPOSALS;
NEGATIVE REGULATOR;
MOUSE DEVELOPMENT;
D O I:
10.1172/JCI45784
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Biochemical studies have suggested conflicting roles for the E3 ubiquitin ligase constitutive photomorphogenesis protein 1 (Cop 1; also known as Rfwd2) in tumorigenesis, providing evidence for both the oncoprotein c-Jun and the tumor suppressor p53 as its targets. Here we present what we believe to be the first in vivo investigation of the role of Cop1 in cancer etiology. Using an innovative genetic approach to generate an allelic series of Cop1, we found that Cop1 hypomorphic mice spontaneously developed malignancy at a high frequency in the first year of life and were highly susceptible to radiation-induced lymphomagenesis. Further analysis revealed that c-Jun was a key physiological target for Cop1 and that Cop1 constitutively kept c-Jun at low levels in vivo and thereby modulated c-Jun/AP-1 transcriptional activity. Importantly, Cop1 deficiency stimulated cell proliferation in a c-Jun-dependent manner. Focal deletions of COP1 were observed at significant frequency across several cancer types, and COP1 loss was determined to be one of the mechanisms leading to c-Jun upregulation in human cancer. We therefore conclude that Cop1 is a tumor suppressor that functions, at least in part, by antagonizing c-Jun oncogenic activity. In the absence of evidence for a genetic interaction between Cop1 and p53, our data strongly argue against the use of Cop1-inhibitory drugs for cancer therapy.
引用
收藏
页码:1329 / 1343
页数:15
相关论文